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 The prevalence of pulmonary cryptococcosis has increased in the last
twenty years (1).
 Most commonly due to the human immunodeficiency virus(HIV)
epidemic.
 Also seen in solid organ transplant recipients and patients on chronic
immunomodulatory agents or glucocorticoids.
We present the case of a man with rheumatoid arthritis treated with
methotrexate and leflunomide who presented with cavitary lesion and
pneumonia due to an unusual organism.

Case Presentation
 A 57-year-old man with past medical history notable for rheumatoid
arthritis presented with dyspnea on exertion, night sweats, unintentional
weight loss, and cough which had been progressing over the previous
four weeks.
 The patient’s rheumatoid arthritis was well controlled with methotrexate
10mg weekly, prednisone 5 mg daily, and leflunomide 20mg daily. The
patient was in El Paso, Texas and St. Louis, Missouri in the last six months.
 On physical examination, the patient was afebrile and had normal vital
signs. Physical exam revealed decreased breath sounds in his right lower
lung fields. No nuchal rigidity or skin lesions were present.
 Laboratory studies were notable for a white blood cell count of 7.4 x
103/uL with a normal differential and an elevated erythrocyte
sedimentation rate at 72 mm/hr. Serum cryptococcal antigen was
negative.
 Chest radiograph and subsequent computed tomography (CT) of the
chest revealed a right upper lobe cavitary lesion and right lower lobe
consolidation. (Figure 1, 2) A bronchoscopy was performed with
bronchoalveolar lavage (BAL). Fungal culture from the BAL grew
Cryptococcus neoformans (Figure 3 and 4). Head CT and lumbar puncture
revealed no evidence of central nervous system infection. Testing for HIV
was negative.
 Therapy with fluconazole 400 mg daily was initiated with significant
improvement in functional status. Immunosuppressive therapy was
stopped with the exception of low dose prednisone. Given the long halflife of leflunomide (15 days), a washout was performed with
cholestryramine. Antifungal therapy will be continued for six to twelve
months, depending on patient response. All immunomodulatory therapy
will be held during this time.

Figure 1 is a picture of the
Chest X-Ray showing a right
upper lobe cavitary lesion.

Figure 2 is a picture of the CT
scan of the chest, showing a
right sided cavitary lesion.

 Cryptococcus, an opportunistic fungal infection, presents most
commonly as meningitis, but may affect any organ system.
 Isolated pulmonary involvement is the second most common
presentation, with symptoms ranging from asymptomatic
colonization to severe pneumonia with respiratory failure. The
severity of disease is based on degree of immunosuppression in
the affected host. The most common radiographic finding in
non-HIV patients is solitary or multiple pulmonary nodules,
followed by multifocal airspace consolidation. Lobar infiltrates
and
cavitary
lesions
occur
more
commonly
in
immunosuppressed host.
 Diagnosis can be made from culture following sputum sampling,
bronchoscopy with BAL, or open lung biopsy. Serum
cryptococcal antigen detection is highly specific when found in
titers greater than 1:4, though isolated pulmonary involvement
of the non-HIV patient, only 25-56% of patients have positive
titers.
 Treatment largely depends on the patient’s immune status and
extent of disease. Immunocompromised patients with mild to
moderate disease may be treated with fluconazole 400mg daily
for 6-12 months. Severe lung disease or disseminated disease
should be treated with induction therapy with a liposomal
amphotericin and flucytosine combination for 2-4 weeks
followed by fluconazole therapy until immune reconstitution is
achieved.
 Cryptococcal pneumonia has been reported with methotrexate
concurrent with steroid or leflunomide therapy.
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Figure 3 and 4 show microscopic examination of
sputum fungal culture specimen obtained by
performing brocnchoscopy with BAL. Figure 4 shows
presence of encapsulated yeast on India Ink stain,
hallmark or Cryptococcus.
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